Background/Aims: The risk of developing pancreatitis induced by endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is relatively small. However, patients undergoing sampling through the normal pancreatic parenchyma or the pancreatic duct may have a higher rate of pancreatitis. Here, we determine the factors associated with increased risk of acute pancreatitis in patients undergoing FNA through normal pancreatic parenchyma/pancreatic duct. Methods: In this prospective study at a tertiary cancer center, patients undergoing sampling through the pancreatic duct or ≥5 mm of the normal parenchyma between December 2013 and September 2017 were included. Post-EUS induced pancreatitis was diagnosed by the presence of abdominal pain with an amylase or lipase level higher than three times normal value. Results: A total of 712 patients underwent pancreatic EUS FNA. A total of 163 patients were included in the high-risk group. Mean age was 63 years, 82 females, mean number of needle-passes was 3.3 (range, 1-7). Fifteen patients (15/163, 9.2%) developed pancreatitis after EUS FNA through the pancreatic parenchyma compared with only one case among the control group (<5 mm of normal parenchyma) (0.18%, 1/549, p<0.0001). Several factors appeared to be associated with pancreatitis, including young age, solid lesion, and a recent history of acute pancreatitis. By logistic regression, a prior history of recent pancreatitis was the only statistically significant factor associated with post-EUS-guided biopsy pancreatitis (p=0.008). Conclusions: Patients with a recent history of acute pancreatitis undergoing EUS FNA through 5 mm or more of the normal pancreatic parenchyma are at a much greater risk of acute pancreatitis. (Korean J Gastroenterol 2018;72:135-140) 
INTRODUCTION

Among all patients undergoing endoscopic ultrasound (EUS)
for pancreaticobiliary indication, pancreatitis is an uncommon complication, reported only in 1-2% of all cases.
1,2 EUS-guided biopsy of the pancreas can usually be performed avoiding the pancreatic duct (PD) and/or passing a needle through a significant portion of the normal pancreatic parenchyma, which might help decrease the rate of post-EUS fine needle aspiration (FNA) pancreatitis. It is also possible that some cases may go unnoticed due to milder clinical presentation or symptoms that can be confused with the underlying diseases, such as pancreatic cancer or chronic pancreatitis.
Moreover, the nature of retrospective study also contributed to the under-reporting of this complication. 3 It is accepted that when the needle traverses the normal parenchyma and/or PD, the rate of pancreatitis may be higher, although this concept is based on scarce data. 4 Other factors have been shown to be associated with post-EUS pancreatitis; for example, patients with recent history of acute pancreatitis may be exposed to a greater risk or when FNA of side branchintraductal papillary mucinous neoplasm (IPMN) results in injury to nearby PD. 4, 5 In one of the first publications raising concerns about the sampling of normal parenchyma came
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(1/18, 5.5%). Because of the limited diagnostic yield and higher complication rate, the authors recommended against core biopsy of the normal parenchyma in 2005. Since then, other reports confirmed that EUS FNA can result in severe acute pancreatitis. 3, 7 The recent increase use of newly designed core biopsy needles may potentially increase the rate of pancreatitis.
In a large North American multicenter study using the SharkCore fine needle biopsy (FNB) needle (Medtronic, Dublin, Ireland), the rate of pancreatitis was 2.9% and post-procedure abdominal pain was 2.2%. 8 As the authors revealed, this rate was higher than the anticipated rate for EUS FNA of the pancreas (<1%). Because the overall rate of post-EUS FNA pancreatitis is still low in the universe of patients undergoing pancreaticobiliary EUS, we have selected patients at higher risk based on our hypothesis (sample through normal parenchyma or PD) for a prospective study. Our aims were to determine the rate of pancreatitis and evaluate the associated risk factors in patients undergoing EUS FNA through substantial portion of the normal pancreas (≥5 mm) and through the pancreatic duct. The low risk group comprised of patients that were sampled through less than 5 mm of the normal pancreas.
SUBJECTS AND METHODS
Procedures were performed at the Endoscopy suite of the Values are presented as n (%). PD, pancreatic duct. es, history of recent acute pancreatitis (<1 year), previous procedure related pancreatitis, presence of chronic pancreatitis by EUS, and post-procedure pain.
Statistical analysis
Each EUS procedure was considered a data point.
Categorical variables were reported as frequency with percentages, and contiguous variable were reported as the mean. were successfully followed-up post-procedure. Two patients were admitted for pain control and pancreatitis was ruled out 
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The rate of pancreatitis by each parameter was also calculated ( 
DISCUSSION
In this study, we have confirmed that the rate of pancreatitis in a subset of patients undergoing biopsy through the normal pancreatic parenchyma or the pancreatic duct is significantly higher than those undergoing FNA through minimal or none of the normal parenchyma (9.2% vs. 0.18%). Our data is in accordance with the results presented by Katanuma et al. 4 , who in a retrospective study also identified a higher risk of pancreatitis when the needle was advanced through the normal parenchyma. The authors reported that in 73% of patients who had an adverse event (pancreatitis, abdominal pain and bleeding), the needle traversed the normal parenchyma.
Univariate analysis indicated that smaller tumors and cases
where the needle had to traverse normal parenchyma were strongly associated with post-procedure adverse event. 4 In our case, the rate increased, which may be explained by the prospective study design and a very strict follow-up regimen that allowed us to improve the diagnostic rate of acute pancreatitis even beyond the first 24 hours post-procedure. Moreover, pancreatic duct aspiration, which had the highest rate of pancreatitis (17.6%), was done in 17 patients who skewed our rate even higher. Furthermore, the majority of the study population (87.1%) was comprised of benign disease which resulted often sampling through the normal parenchyma at times with multiple biopsies. Patients with malignant disease have a lower rate of pancreatitis after EUS FNA and are underrepresented in this group. 10 The factors associated with post-procedure pancreatitis in this series were: sampling through the normal pancreatic parenchyma and history of acute pancreatitis. FNA through PD had the highest rate of pancreatitis, but due to small sample size, we could not identify a statistically significant difference. Therefore, based on our collected data to date, we suggest that FNA through PD should be limited and reserved to cases where it will impact clinical decision. After applying a regression analysis for several dichotomous variable, recent history acute pancreatitis was the strongest predictor of post EUS pancreatitis. Other EUS studies have also noted that a recent history of pancreatitis is a predictor of this complication. 5, 11 It is recommended that one should wait at least up to 8 weeks for the episode of pancreatitis to resolve prior to FNA. 12 However, if one suspects malignancy, waiting eight weeks seems like an unreasonably long time and FNA must be performed sooner, given the increased rate of pancreatitis.
We selected FNA through >5 mm of the normal pancreatic parenchyma as the inclusion criteria for the high-risk group in the current study. In fact, this group had a much higher rate than the control, but when we compared the subgroup with more than 10 mm of needle insertion (78 patients, see Table   1 ) to less than 10 mm, there was no difference in the rate of pancreatitis. Based on these findings, it seems that pan- Our study has some limitations. First, newer needle devices
were not used in this study, which would have allowed for better core samples with fewer needles passes potentially decreasing the rate of pancreatitis or may be increasing if newer needles designs lead to more injury to the pancreatic parenchyma. Second, our study included a limited number of patients with malignant disease who have usually a much lower rate of post EUS FNA pancreatitis. Finally, our control group was prospectively obtained from an automated call system, and a GI nurse could have also missed a few cases of pancreatitis; however, this was certainly not to the extent that would significantly increase the rate of pancreatitis in the control group and nullify the difference encountered.
In summary, patients with a history of recent acute pancreatitis undergoing EUS FNA through 5 mm or more of the normal pancreatic parenchyma are at an increased risk of post-EUS FNA pancreatitis. In such cases, an alternative diagnostic method should be considered. We are currently evaluating whether indomethacin suppository may ben beneficial to this particular group in the prevention of acute pancreatitis post-EUS FNA.
